VARIOUS FORMULATION VARIABLES EFFECTING FLOATATION BEHAVIOUR OF SINGLE UNIT GASTRORETENTIVE CAPSULES OF OFLOXACIN
DOI:
https://doi.org/10.22159/ijpps.2017v9i1.13962Keywords:
Gastro-retentive, Matrix integrity, Floating time, Ofloxacin, HPMC, EudragitAbstract
Objective: Objective of the present study was to prepare simple single unit gastro-retentive capsules of ofloxacin with the aim to have the gastric retention of the system for longer periods of time (12h) and to study the effect of various polymers on floating behaviour of such single unit gastro-retentive capsules of ofloxacin.
Methods: The method used for the preparation of gastro-retentive capsules was a simple physical blending of various low-density hydrophilic polymers alone and in combination with hydrophobic polymers and filling into capsules. These capsules were then subjected to in vitro floatation and matrix integrity study in 0.1N HCl using static volume beaker method and the United States pharmacopoeia (USP) type II dissolution apparatus method at 100rpm.
Results: Two grades of hydroxypropyl methylcellulose (HPMC) K4M and K15M used were found suitable for the purpose. Results showed that increase in HPMC level increased colloidal gel barrier strength along with matrix integrity with consequently improved buoyancy. Lactose which was added as release rate modifier decreased matrix integrity and buoyancy. Eudragit a hydrophobic polymer was added so as to have intact, the buoyant formulation for 12 h with desired drug release characteristics. The addition of eudragit enhanced matrix integrity and floatation time to certain levels but higher levels showed negative results. Floatation time of more than 16 h was observed in the formulations containing 2:1 ratio of HPMC K15M and eudragit respectively. 32 factorial design was used to study the effect of various formulation variables on buoyancy and matrix integrity. Formulations containing zero level of HPMC were found buoyant for more than 12 h with all levels of eudragit S100 (i.e.,-1, 0,+1 level). It was also observed that matrix integrity consequently buoyancy increased with increase in eudragit with all levels of HPMC.
Conclusion: The study concludes that eudragit S100 a hydrophobic polymer increased floatation time of the formulated capsules with all the three levels of HPMC K15M, but at the same time eudragit level should not exceed HPMC, while lactose a release rate enhancer decreased matrix integrity/floatation time of the formulated capsules.
Downloads
References
Ummadi S, Shravani B, Rao NGR, Reddy MS, Sanjeev B. Overview on controlled release dosage form. Int J Pharma Sci 2013;3:258–69.
Chhetri HP, Thapa P. An overview on gastro retentive drug delivery system. Kathmandu Univ J Sci Eng Technol 2014;10:90–103.
Etman ME, Mahmoud EH, Galal S, Nada AH. Floating ranitidine micro particulates: development and in vitro evaluation. Int J Appl Pharm 2016;8:1–9.
Kale RD, Tayade PT. A multiple units floating drug delivery system of piroxicam using eudragit polymer. Indian J Pharm Sci 2007;69:120–3.
Raza S, Khan N. Gastric retention–an innovative approach to increasing bioavailability. Int J Biol Pharm Allied Sci 2014;3:113–33.
Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems: a review. Asian J Pharm Clin Res 2010;3:2–10.
Rednick AB, Tucker SJ. Sustained release bolus for animal husbandry. United States Patent 3507952; 1970. p. 1–7.
Davis SS, Stockwell AF, Taylor MJ, Hardy JG, Whalley DR, Wilson CG, et al. The effect of density on the gastric emptying of single and multiple-unit dosage forms. Pharm Res 1986;3:208–13.
Mamajek R, Moyer ES. Drug dispensing device and method. United States Patent 4207890; 1980.
Urquhart J, Theeuwes F. Drug delivery system comprising a reservoir containing a plurality of tiny pills the United States Patent 4434153; 1984.
Ponchel G, Irachi J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Delivery Rev 1998;1:191–219.
Fix J, Cargill R, Engle K. Controlled gastric emptying. III. The gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm Res 1993;10:1087–9.
Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Controlled Release 1999;58:195–205.
Deshpande A, Shah NH, Rhodes TC, Malick W. Development of a novel controlled release system for gastric retention. Pharm Res 1997;14:815–9.
Groning R, G Heun. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm 1984;10:527–39.
Lahoti SR, Shinde RK, Ali SAy, Guleeha B. PH triggered sol-gel transition system of ofloxacin for prolonged gastric retention. Der Pharm Sin 2011;2:235–50.
Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK, et al. Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2007;67:196–201.
Sathiyaraj S, Devi RD, Hari VBN. Lornoxicam gastro retentive floating matrix tablets : design and in-vitro evaluation. J Adv Pharm Technol Res 2011;2:156–62.
Remya PN, Damodharan N, Priyadarsini SG, Prabaharan K. Effect of various surfactants on release behaviour of furosemide from floating tablets. Int J Pharm Pharm Sci 2010;2:2–5.
Yin L, Qin C, Chen K, Zhu C, Cao H, Zhou J, et al. Gastro-floating tablets of cephalexin: preparation and in vitro/in vivo evaluation. Int J Pharm 2013;452:241–8.
Cheong LWS, Heng PWS, Wong LF. The relationship between polymer viscosity and drug release from a matrix system. Pharm Res 1992;9:1510–4.
Tiwari S, Rajabi-Siahboomi AR. Modulation of drug releases from hydrophilic matrices. Pharm Technol Eur 2008;20:24–32.
Jamzad S, Fassihi R. Development of a controlled release low dose class II drug-Glipizide. Int J Pharm 2006;312:24–32.
Rahman M, Hasan S, Alam A, Roy S, Jha MK, Ahsan Q, et al. Formulation and evaluation of ranolazine sustained release matrix tablets using eudragit and HPMC. Int J Pharm Biomed Res 2011;2:7–12.
Lee BJ, Ryu SG, Cui JH. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev Ind Pharm 1999;25:493–501.
Published
How to Cite
Issue
Section
